The Canadian Cancer Survivor Network notes that the 2026 Ontario Budget does not include expanded public funding for take-home cancer drugs. While important investments have been made in other areas, the omission of this recommendation continues to leave many cancer patients and survivors without equitable access to affordable, lifesaving medication.
Earlier this year, CCSN participated in Ontario’s pre-budget submission process wherein we recommended that the government include expanding its public funding for take-home cancer drugs. During the in-person consultations, CCSN Executive Director Lindsay Timm emphasized that take-home cancer drug coverage could be implemented using Ontario’s existing drug benefits infrastructure, without requiring new or complex administrative systems. She also noted that there are many factors affecting equitable access to take-home cancer drugs that could be lessened by having a provincially funded program.
By not funding take-home cancer drugs, the burden that currently exists on the healthcare system is maintained. By allowing patients and survivors improved access to take-home cancer drugs, the amount of care needed in a hospital or cancer centre can be reduced, thereby alleviating the burden and optimizing resources within clinical settings for patients who require in-person care. A healthy Ontario economy is supported by healthy citizens, and ones who are not worrying about how to pay for cancer drugs that are already covered in-hospital.
While CCSN’s recommendation is absent in the 2026 Budget, we acknowledge and commend the Ontario government’s continued support of cancer patients provided through the Ontario Trillium Benefit and the Exceptional Access Program. These programs are vital lifelines for many cancer patients and survivors, and we are grateful that they remain in place to provide assistance where possible.